Evaluation of serum fibronectin levels and fibronectin gene polymorphism in patients receiving intravesical BCG therapy for non-muscle invasive bladder cancer and its prognostic value

Ali Nebioğlu,Rojda Tanrıverdi,Mert Başaranoğlu,Barış Saylam,Ercüment Ulusoy,Murat Bozlu,Erdem Akbay,Lülüfer Tamer,Semra Erdoğan
DOI: https://doi.org/10.1186/s12894-024-01592-8
2024-09-29
BMC Urology
Abstract:Bladder cancer continues to be a significant health issue, leading to ongoing research into novel biomarkers and treatment strategies. This study aims to evaluate the potential of serum fibronectin levels and fibronectin gene polymorphisms as biomarkers for predicting the recurrence and treatment response in patients with NMIBC undergoing intravesical BCG therapy.
urology & nephrology
What problem does this paper attempt to address?